Scepter Holdings, Inc., Excited to Announce Nosebudz(R) Nasal Air Filters Available for Purchase on Amazon.com

LAS VEGAS, NV / ACCESSWIRE / October 20, 2020 / Scepter Holdings, Inc., (OTC PINK:BRZL) a high-performance consumer goods sales and marketing company, is pleased to announce that Nosebudz® Nasal Air Filters are now available for purchase from Amazon.com.

NoseBudz is a simple, innovative, nasal air filter designed to stop aerosolized viral particles and allergens. The unique patent-pending conical filters in NoseBudz are designed to filter particles one-micron or larger, while maintaining sufficient airflow to allow normal breathing through the nose.

This past April, Scepter Holdings signed an exclusive sales and marketing agreement with Dr. Robert Brunst to market his innovative NoseBudz nasal air filter. Since that time, the Scepter and Nosebudz teams have worked together to introduce NoseBudz for sale on Amazon. Launching NoseBudz for sale on Amazon is the first step in a longer promotional campaign to promote and grow the NoseBudz brand.

“We are pleased to see the results of our hard work, bringing NoseBudz back to market, at a time when consumer demand for personal safety products is at an all-time high,” stated Adam Nicosia, Vice President of Sales at Scepter Holdings, Inc.

About Scepter Holdings, Inc.

Scepter Holdings, Inc. (the “Company”) manages the sales and brand development of high-performance consumer packaged goods. The company seeks to acquire performing brands to add to the company’s portfolio of products and brands sold online and through strategic retail relationships. The company has expertise manufacturing, distributing, marketing, and selling online consumer packaged goods and seeks to leverage its expertise to grow additional acquired brands. Scepter Holdings, Inc. was incorporated under the laws of the State of Nevada on January 11, 2007.

For more information, please visit our website: http://scepterbrands.com

Forward-Looking Statements

This news release may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including economic slowdown affecting companies, our ability to successfully develop products, rapid change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Scepter Holdings, Inc. filings with the Securities and Exchange Commission, which factors may be incorporated herein by reference. Forward-looking statements may be identified but not limited by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” and variations or similar expressions. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Investors Contact:

775-296-5768
info@scepterbrands.com

SOURCE: Scepter Holdings, Inc.

View source version on accesswire.com:
https://www.accesswire.com/611258/Scepter-Holdings-Inc-Excited-to-Announce-NosebudzR-Nasal-Air-Filters-Available-for-Purchase-on-Amazoncom

Staff

Recent Posts

TestoPrime Review: Why TestoPrime Is Better Than Other Testosterone Booster Supplement in 2025?

TestoPrime is a top rated, all natural testosterone booster for men in their 40's and…

1 hour ago

Lipozem Reviews: Does It Really Work For Weight Loss in 2025?

Lipozem: We Tested Lipozem Supplement - Here Is Our Honest Review NEW YORK CITY, NY…

1 hour ago

Assessing Post-Cardiac Surgery Kidney Recovery Through PenKid’s Emerging Role in Renal Replacement Therapy Decisions

Proenkephalin A 119-159 (penKid) demonstrates potential as a predictor for successful discontinuation of continuous renal…

1 hour ago

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates

Ad hoc announcement pursuant to Art. 53 LR Revenue Growth: Full-year 2024 revenue of €265.7…

5 hours ago

RiDYMO® Designs Cyclic Peptide for “Undruggable” β-Catenin Target Within Two Months

BEIJING, Jan. 8, 2025 /PRNewswire/ -- In a recent achievement, DP Technology's hit discovery platform RiDYMO® has…

7 hours ago